Uncategorized Archives | MPM BioImpact

26th June 2025

Chris Bardon is featured with UBS CIO Mark Haefele on the AACR Believe in Progress podcast

25th June 2025

āshibio Doses First Patient in Phase 1b Trial of Andecaliximab in Patients with Spinal Cord Injury (SCI) at Risk of Heterotopic Ossification (HO)

31st March 2025

Orna Therapeutics Appoints Joseph Bolen, Ph.D., an MPM BioImpact Entrepreneur Partner, as Chief Executive Officer

28th March 2025

DBV Technologies Announces PIPE of up to $306.9 Million, Led by MPM BioImpact

29th January 2025

Cullinan Therapeutics Announces Primary Endpoint Met in Phase 2b Trial of Zipalertinib

8th January 2025

MPM BioImpact Appoints Brian Shuster, Experienced in Healthcare Corporate Development, as Entrepreneur Partner

8th January 2025

MPM BioImpact Announces Promotion of Rami Rahal, Ph.D., to Partner

7th January 2025

Orna Therapeutics Establishes Strategic Collaboration with Vertex Pharmaceuticals to Develop Next Generation Approaches for Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT)